Name: Interview with Professor Alexandre Mebazaa
Uploaded: 2026-03-06T09:52:02.000Z
Duration: 9 min 34 s
Description: Thousands of YouTube videos with English-Chinese subtitles! Now you can learn to understand native speakers, expand your vocabulary, and improve your pronunciation...

I am a professor of critical care in the University of Paris.

Past simple

I started research in cardiovascular area since many years.

To-infinitive

And very quickly it appears that biomarkers is a novel area and very exciting area, because we could try to assess the function of some organs by measuring the biomarkers upstream or downstream those organs and these five to 10 years ago, we started to work on biomarkers.

And what is very exciting now is that we are discovering that among the biomarkers, some have no biological activities, those have a biological activity.

And what is very, very exciting is that the biomarkers with the biological activity, we can try to modulate their activity.

Then we are moving from biomarker to bio targets.

This is a little bit in the cardiovascular area and in the acute critical care area.

And I'm putting a lot of efforts to have all the young fellows, young residents coming to our research group to learn what is research biomarkers of the future came because many people in my group, many people, part of our international collaborations, together with me, we discovered that indeed we are very expert in cardiovascular area.

We are very expert in the critical care, but

we discovered that people from other areas are doing excellent research in cancer and infectious disease.

And there are new tools that are coming that are maybe more developed in some research area and others in other research area.

And we thought that we need really to learn from each other.

And this reason why we put together this conference and we asked the senior people who are doing those research to come and tell all of us what is really new.

But maybe as importantly, during this biomarker of the future, it's also the room for very, very young fellows who are just doing their first research and who are successful in this research and biomarker to come and to present their last work.

And this competition was already a success since a few years.

And this year already is also a big success with a very large number of abstracts.

Again, this biomarker of the future is the meeting of the senior researcher, but

also the young researcher, the competition, we started it on the first biomarker event.

And when we had a discussion with Olink, they immediately understood that showing data from the young researcher, having the young researchers coming to this meeting is important.

And now everybody is convinced that we were right to do so.

This year we have a very large number of abstracts with a very high quality.

Now, indeed, we couldn't listen to all the research that was sent to us.

We will shortlist it and we have already shortlisted 10 fellows and really bravo to those 10 fellows.

Now they have to work, they have to have a great presentation.

They have also to answer to the questions.

The jury is a tough jury, it's an international jury.

But this jury is going to be very nice with those 10 fellows and we'll be happy to see really brand new research and really for the young fellows, it's an incredible opportunity to be visible, to interact and many of those fellows become friends and many of the fellows who are participating to this contest and won the prizes have usually a great publication.

Then really, I really advise all the young researchers to attend, to listen to this competition and even make their choice and also participate with this competition in the following years.

In my research we are using different tools and indeed we are using also proteomics.

And what is really great, using proteomics, is it open your eyes.

In other specialties and in a recent research that is ongoing right now, by using proteomics, we discovered that immunological path was altered.

And then I went to see experts in that area and we interacted.

They were happy, we were happy and we learned a lot.

Proteomic means putting several specialties together, having several specialties, talking to each other, but

having also engineers and biostatisticians who are coming and also bringing their expertise.

And it's really an incredible opportunity to learn many new things, but also to interact with many specialties.

Proteomic will bring a lot to the health care community first because it's going to help us showing novelties for many years.

We're thinking research and medicine as a silo, that disease is a cardiovascular disease, that disease is a kidney disease.

And we know today that this is not true, that there are common paths that make several organs sick and with altered function.

And proteomics is going not only to show how wide is the alteration, how many organs are altered, how many paths are altered, but

also show the balance between maybe that organs that is more altered than in others, and

maybe more importantly it shows the benefits of the drugs.

We have a recent study that we are finishing to study where we showed that a drug that has a beneficial effect for years, we are thinking that the effect is related to vascular disease and we are discovering that it's also having some benefits on coagulation and inflammation.

Then you see, proteomics is giving you really a wider picture, probably a more correct picture on.

When I started as a resident in intensive care medicine.

My senior physicians were often telling me, okay, you do that medication for that disease and you do not do that medication to the other disease.

And I was always asking why and how come?

And sometimes the answer was a clear answer based on data and, and

many times in intensive care area the answer was we don't know.

And this reason why I thought that I need really to go to research to try to understand step by step things to try to understand disease, try to understand therapies, try to use our patients and put them in a network to see that in fact there is a huge community all around the world having the same target, the same aim, which is to treat patients.

And as you know, in intensive care we have a the mortality rate is very high in our beds.

And then it's an everyday fight to try to make those patients surviving, even those patients having a great quality of life when they go out.

And the only way to have those patients surviving is to understand the disease.

And what is really also great by doing research is in our research group, for instance, we have many residents, many fellows coming from all around the world.

In my lab right now, we have fellows from Japan, we used to have fellow from Finland, from Turkey, from Spain, all on the same lab, talking together.

And this is going to be the next generation of researcher and of clinicians.

And this is something that you see only when you are doing research, because everybody is motivated by the same thing as try to save patients lives and try to improve their quality of life.